What is Endovascular Engineering?
Headquartered in Menlo Park, CA, Endovascular Engineering is a mission-driven, venture-backed company focused on the development and deployment of next-generation clot removal technologies targeting venous thromboembolism. The company's innovative approach aims to significantly improve patient outcomes in the treatment of this critical condition. As a company operating in the highly competitive MedTech space, Endovascular Engineering's progress is closely watched by industry peers and investors alike, given the substantial unmet need for effective and less invasive treatment options.
How much funding has Endovascular Engineering raised?
Endovascular Engineering has raised a total of $122M across 2 funding rounds:
Series B
$42M
Series C
$80M
Series B (2025): $42M with participation from S3 Ventures, 415 Capital, M&L Healthcare, and Santé Ventures
Series C (2026): $80M led by Panakes Partners, Norwest Venture Partners, S3 Ventures, Venture Capital, Santé Ventures, and Gilde Healthcare
Key Investors in Endovascular Engineering
S3 Ventures
S3 Ventures is a prominent venture capital firm based in Austin, Texas, known for its patient and flexible investment approach. They specialize in business technology, digital experiences, and healthcare technology, providing significant backing to early-stage companies.
415 Capital
415 Capital LLC operates within the Venture Capital & Private Equity sector, focusing on innovative medical technologies. Based in San Francisco, they provide capital and expertise to companies aiming to advance healthcare solutions.
Santé Ventures
Santé Ventures is a dedicated investment firm managing over $1 billion, focusing on innovative healthcare and technology companies. They actively seek visionary entrepreneurs in Biotech, Medtech, and Healthtech to enhance patient health outcomes.
What's next for Endovascular Engineering?
With the recent infusion of $80M in a major strategic investment, Endovascular Engineering is poised for accelerated growth and market penetration. This substantial backing, part of its overall $122M in capital, suggests a transition into a scaling phase, likely focusing on expanding clinical trials, scaling manufacturing capabilities, and broadening its commercial reach. The company's strategic focus on venous thromboembolism positions it to address a significant global health challenge, with future developments expected to further solidify its market leadership in endovascular therapies.
See full Endovascular Engineering company page
